A multi-centre, double-blind dose-ranging study to evaluate the efficacy and safety/tolerability of Birch Modified Allergen Tyrosine-adsorbed + MPL (POLLINEX Quattro® Birch) in Subjects with seasonal allergic rhinoconjunctivitis due to birch pollen

Trial Profile

A multi-centre, double-blind dose-ranging study to evaluate the efficacy and safety/tolerability of Birch Modified Allergen Tyrosine-adsorbed + MPL (POLLINEX Quattro® Birch) in Subjects with seasonal allergic rhinoconjunctivitis due to birch pollen

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Apr 2015

At a glance

  • Drugs Birch pollen allergy immunotherapy (Primary)
  • Indications Allergic rhinoconjunctivitis; Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Sponsors Allergy Therapeutics
  • Most Recent Events

    • 11 Oct 2014 Status changed from recruiting to completed as reported by European Clinical Trials Database.
    • 22 Sep 2014 Results published in an Allergy Therapeutics media release.
    • 22 Sep 2014 Primary endpoint (Change from baseline to post-treatment in total symptom score (TSS) following conjuctival provocation tests) has been met, according to an Allergy Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top